- 期刊
Genetic Studies in Acute Lymphoblastic Leukemia
並列摘要
As the long-term event-free survival rate in children with acute lymphoblastic leukemia approaches 80%, emphasis is being placed on risk-directed therapy to prevent over-or undertreatment. It has become apparent that risk assignment based on primary genetic abnormalities is inadequate by itself, and that measurement of early responses to therapy and the extent of minimal residual disease is needed to improve the accuracy of risk classification. Studies to identify genetic polymorphisms with pharmacokinetic and pharmacodynamic significance promise to enhance the discovery of new drugs and to optimize chemotherapy. Recent successes in directing therapy to specific genetic abnormalities demonstrate the feasibility of molecular medicine for the childhood leukemias, and predict the development of highly effective drug regimens with minimal toxicity against normal hematopoietic cells.
延伸閱讀
- Chen, B. W., Lin, K. H., Lin, D. T., chuu, W. M., Su, S., & Lin, K. S. (1989). An Analysis of Risk Factor and Survival in Childhood Acute Lymphoblastic Leukemia. Acta Paediatrica Sinica, 30(5), 299-308. https://www.airitilibrary.com/Article/Detail?DocID=00016578-198910-30-5-299-308-a
- Yu, C. H. (2020). Genetic Profiling of Pediatric B-cell Acute Lymphoblastic Leukemia [doctoral dissertation, National Taiwan University]. Airiti Library. https://doi.org/10.6342/NTU202001830
- Pui, C. H. (2004). Recent Advances in Childhood Acute Lymphoblastic Leukemia. Journal of the Formosan Medical Association, 103(2), 85-95. https://doi.org/10.29828/JFMA.200402.0002
- 趙美琴、陳添享、江季勛（1982）。Cytogenetic Studies on Acute Lymphoblastic Leukemia in Children。Acta Paediatrica Sinica，23(1)，36-44。https://www.airitilibrary.com/Article/Detail?DocID=00016578-198203-23-1-36-44-a
- 侯信安、柯博升、田蕙芬（2008）。Chronic Lymphocytic Leukemia。當代醫學，(422)，973-976。https://doi.org/10.29941/MT.200812.0015